GSK, Pfizer And Shionogi-owned ViiV Healthcare Will Make At Least 2M Doses Of Long-Acting Cabotegravir For HIV Pre-exposure Prophylaxis Available For Procurement For Low- And Middle-Income Countries During 2025-2026, Tripling From 2024
Portfolio Pulse from Benzinga Newsdesk
GSK, Pfizer, and Shionogi's ViiV Healthcare will produce at least 2 million doses of long-acting Cabotegravir for HIV prevention for low- and middle-income countries in 2025-2026, tripling the amount from 2024.
October 07, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK, through ViiV Healthcare, will significantly increase production of Cabotegravir for HIV prevention, enhancing its role in global health initiatives.
GSK's involvement in increasing Cabotegravir production highlights its commitment to global health, potentially boosting its reputation and market position.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, as part of ViiV Healthcare, is involved in the increased production of Cabotegravir, aligning with its healthcare initiatives.
Pfizer's participation in this initiative may enhance its image in global health efforts, potentially benefiting its market perception.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 60